This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Pelli-Robson | |
|---|---|
| Name | Pelli-Robson chart |
| Purpose | Contrast sensitivity testing |
| Developer | Dame Jean Dorothy Pelli; William H. Robson |
| Introduced | 1988 |
| Field | Ophthalmology; Optometry |
| Related | Snellen chart; LogMAR chart; Freiburg Visual Acuity Test |
Pelli-Robson The Pelli-Robson chart is a clinical tool for measuring contrast sensitivity in human vision, designed to quantify the lowest contrast at which letter optotypes are recognized. It is widely used in Ophthalmology and Optometry clinics, vision science laboratories, and in research involving visual function in conditions such as Age-related macular degeneration, Diabetic retinopathy, and Glaucoma. The chart complements high-contrast visual acuity tests by assessing suprathreshold spatial contrast processing related to everyday tasks like driving and face recognition.
The chart evaluates contrast sensitivity primarily at mid-spatial frequencies using rows of large letters arranged in triplets, permitting standardized assessment across populations including patients seen at institutions such as Moorfields Eye Hospital, Johns Hopkins Hospital, and Bascom Palmer Eye Institute. Development and dissemination have involved collaborations among academic centers including New York University and University College London, and professional societies like the American Academy of Ophthalmology and American Optometric Association have incorporated contrast testing into clinical guidelines. The instrument is applicable for epidemiological studies such as those conducted by the Beaver Dam Eye Study and clinical trials sponsored by the National Eye Institute.
The Pelli-Robson chart uses 2.8-degree uppercase letters in a sans-serif font similar to that used for optotype standards promulgated by organizations including the International Organization for Standardization and the British Standards Institution. Letters are arranged in groups of three, with each subsequent triplet reduced in contrast by a factor of 0.15 log units; the design allows quantification on a log contrast sensitivity scale. Standard administration follows illumination and viewing distance protocols consistent with recommendations from ISO 8596 and practice parameters from the American Academy of Ophthalmology and College of Optometrists (UK). Testing is typically binocular and monocular at 1 meter or 3 meters, performed under controlled luminance conditions akin to those specified by the Illuminating Engineering Society.
Test procedure requires careful control of chart luminance, room lighting, and refractive correction; clinicians often follow protocols similar to those at Massachusetts Eye and Ear Infirmary or Wills Eye Hospital. Responses are recorded as the last triplet with two or more correct letters, and clinicians may use trained examiners from clinics like Wilmer Eye Institute to improve reliability.
Scores are reported in log contrast sensitivity units, with normal young-adult population values typically near 2.0 log units under standardized conditions in studies from centers such as Queensland Institute of Medical Research and University of Melbourne. Lower scores indicate reduced contrast sensitivity associated with pathologies managed at institutions like Moorfields Eye Hospital and Bascom Palmer Eye Institute. Interpretation integrates comparisons to normative datasets from population studies including Blue Mountains Eye Study and Beaver Dam Eye Study, and to functional outcomes used in trials by the National Eye Institute.
Clinicians translate Pelli-Robson scores into functional prognosis for tasks regulated by agencies such as the Federal Aviation Administration and Department of Transportation where contrast thresholds affect driving and licensing considerations. Repeatability and test–retest variability reported in multicenter research involving NEI investigators inform clinical decision thresholds.
Pelli-Robson testing is used in the evaluation of visual impairment in conditions including Age-related macular degeneration, Glaucoma, Diabetic retinopathy, Cataract, and neurological disorders evaluated at centers like Massachusetts General Hospital and Mayo Clinic. It is valuable for assessing visual effects of interventions from trials at Bascom Palmer Eye Institute and Johns Hopkins School of Medicine, including outcomes after cataract surgery, anti-VEGF therapy for AMD, or glaucoma filtration procedures. Low contrast sensitivity predicts difficulties in daily activities documented in studies associated with University of California, San Francisco and Harvard Medical School.
The chart is also used in regulatory and occupational assessments by agencies such as the Federal Aviation Administration and in research funded by the National Institutes of Health and MRC.
Pelli-Robson emphasizes mid-spatial-frequency contrast sensitivity and may be less sensitive to deficits at high spatial frequencies compared with tests developed at institutions like University College London or laboratories such as the Smith-Kettlewell Eye Research Institute. Its psychometric step size of 0.15 log units balances clinical efficiency against resolution; however, ceiling and floor effects occur in highly functioning or severely impaired patients. Contrast sensitivity measured with the chart can be affected by factors studied at centers such as Johns Hopkins Hospital and University of Pennsylvania including ambient luminance, cataractous media opacity, uncorrected refractive error, and cognitive factors addressed in research at Stanford University and University of Cambridge.
Reliability and validity metrics have been established in multicenter studies involving NEI investigators and the International Council of Ophthalmology, but clinicians should consider complementary tests for comprehensive evaluation.
The chart was introduced in the late 1980s by researchers including Dame Jean Dorothy Pelli and William H. Robson with methodological foundations from psychophysicists influenced by work at University College London, New York University, and Smith-Kettlewell Eye Research Institute. Subsequent validation and normative studies involved investigators at Moorfields Eye Hospital, Wilmer Eye Institute, Bascom Palmer Eye Institute, and organizations such as the National Eye Institute and World Health Organization which promoted standardization in visual function assessment.
Key contributions to contrast sensitivity measurement trace to earlier psychophysical studies by figures associated with Physiological Optics laboratories at University of Cambridge and Massachusetts Institute of Technology.
Compared with the Functional Acuity Contrast Test (FACT) and sine-wave grating tests used in laboratories at University College London and Smith-Kettlewell Eye Research Institute, the Pelli-Robson chart provides a quick, letter-based clinical measure emphasizing mid-spatial frequencies, unlike high-spatial-frequency resolution emphasized by grating methods developed at MIT and University of Cambridge. Compared with logMAR acuity charts used at International Council of Ophthalmology-aligned clinics, Pelli-Robson assesses contrast rather than minimum angle of resolution, complementing acuity metrics in studies from NEI and Blue Mountains Eye Study. Other letter-based tests such as those from Freiburg University offer alternative scoring conventions and spatial frequency emphases used in research at University of Freiburg.